SubscribeA recent study out of the New York University School of Medicine reveals that the drug Exelon (Rivastigmine) can improve memory in patients who have moderate-to-severe memory loss from traumatic brain injury.
Specifically, improvements were seen in measures of verbal memory and visual processing tasks.
Exelon is normally a drug used to treat memory impairment in patients with Alzheimer’s disease. Its mechanism of action is similar to Aricept (Donezepil) and Razadyne (Galantamine) in that it is thought to enhance cholinergic function in the brain.
The study, however, did not seem to support the effectiveness of Rivastigmine in patients with mild traumatic brain injury (TBI).
Share This Post:![[Slashdot]](http://www.smart-kit.com/wp-content/uploads/_graphics/slashdot-big.png)
![[Reddit]](http://www.smart-kit.com/wp-content/uploads/_graphics/reddit-big.png)
![[Facebook]](http://www.smart-kit.com/wp-content/uploads/_graphics/facebook-icon.gif){kind=icon}
![[Google]](http://www.smart-kit.com/wp-content/uploads/_graphics/google-bookmark-big.png)
![[StumbleUpon]](http://www.smart-kit.com/wp-content/uploads/_graphics/stumble-big.png)
![[Digg]](http://www.smart-kit.com/wp-content/uploads/_graphics/digg-big.png)
Phase II Clinical Trial Begun for Xytis…
Xytis plans to study the effects of anatibant in phase II clinical trials on 400 patientswith moderate to severe closed head traumatic brain injury in nine countries over the next year. Phase I clinical trials showed favorable clinical safety, tolerabi…
[...] exercise (purportedly) can be found everywhere from National Geographic, to AARP, to devoted memory improvement free web sites. Do these digitally mediated cognitive and memory tasks transfer to [...]